The agency contends that DMAA is not backed by safety studies or a relevant history of use and so DMAA is unqualified for use as a New Dietary ingredient.
FDA recently issued warning letters to 10 manufacturers and distributors of dimethylamylamine (DMAA), an ingredient often used in weight loss and bodybuilding dietary supplements. The agency contends that DMAA is not backed by safety studies or a relevant history of use and so DMAA is unqualified for use as a New Dietary ingredient.
DMAA is most commonly used as a thermogenic and a general stimulant. It is often touted as a “natural” stimulant, due to unreliable claims that it is derived from geranium oil. On January 13, 2012, the American Herbal Products Association (Silver Spring, MD) notified all of its members that they should not market DMAA as “geranium oil” or as being any part of the plant.
“There are no known-published reports indicating that [DMAA] is a natural product,” said AHPA chief scientific officer Steven Dentali, PhD. “Any labeling stating that it is naturally occurring in geranium, or any other natural source, would need appropriate scientific evidence to support it.”
FDA’s warning letters note that DMAA is known to narrow the blood vessels and arteries, which can increase one’s risk of serious cardiovascular events. The letter adds that the agency has received 42 adverse event reports from consumers of DMAA products.
Companies that received warning letters have 15 business days to respond to FDA with an outline of how they will address the issues disclosed in the warning letters.
UPDATE, May 3: Attorney Justin Prochnow of Greenberg Traurig LLP (Denver) has notified us of the fact that class action lawsuits have now been filed against 9 of the recipients of FDA DMAA warning letters; the 10th company, USP, had already been sued in February of this year. The class actions were brought by lawfirm Kirtland & Packard LLP (El Segundo, CA). Additionally, Prochnow says, four actions have also been brought against companies that did not receive FDA warning letters but that market DMAA products.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.